334 related articles for article (PubMed ID: 17072120)
41. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
42. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Østergaard L; Van der Wielen M; Bianco V; Miller JM
Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
[TBL] [Abstract][Full Text] [Related]
43. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.
Granoff DM; Harris SL
Pediatr Infect Dis J; 2004 Jun; 23(6):490-7. PubMed ID: 15194828
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
Memish ZA; Dbaibo G; Montellano M; Verghese VP; Jain H; Dubey AP; Bianco V; Van der Wielen M; Gatchalian S; Miller JM
Pediatr Infect Dis J; 2011 Apr; 30(4):e56-62. PubMed ID: 21278617
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
46. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
Kshirsagar N; Mur N; Thatte U; Gogtay N; Viviani S; Préziosi MP; Elie C; Findlow H; Carlone G; Borrow R; Parulekar V; Plikaytis B; Kulkarni P; Imbault N; LaForce FM
Vaccine; 2007 Sep; 25 Suppl 1():A101-7. PubMed ID: 17532101
[TBL] [Abstract][Full Text] [Related]
47. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.
Joseph H; Ryall R; Bybel M; Papa T; MacLennan J; Buttery J; Borrow R
J Infect Dis; 2003 Apr; 187(7):1142-6. PubMed ID: 12660929
[TBL] [Abstract][Full Text] [Related]
49. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
[TBL] [Abstract][Full Text] [Related]
50. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
[TBL] [Abstract][Full Text] [Related]
51. Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.
Bårnes GK; Naess LM; Rosenqvist E; Guerin PJ; Caugant DA;
Scand J Immunol; 2011 Jul; 74(1):87-94. PubMed ID: 21332570
[TBL] [Abstract][Full Text] [Related]
52. Comparison of long-term humoral memory development after immunisation against Neisseria meningitidis B or diphtheria toxoid.
Cruz SC; Silva GP; Sampaio FJ; Souza SL; Dias AA; Milagres LG
Vaccine; 2010 Oct; 28(42):6841-6. PubMed ID: 20719254
[TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
Siberry GK; Warshaw MG; Williams PL; Spector SA; Decker MD; Jean-Philippe P; Yogev R; Heckman BE; Manzella A; Roa J; Nachman S; Lujan-Zilbermann J;
Pediatr Infect Dis J; 2012 Jan; 31(1):47-52. PubMed ID: 21987006
[TBL] [Abstract][Full Text] [Related]
54. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants.
Schmitt HJ; Steul KS; Borkowski A; Ceddia F; Ypma E; Knuf M
Vaccine; 2008 Apr; 26(18):2242-52. PubMed ID: 18407386
[TBL] [Abstract][Full Text] [Related]
55. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
[TBL] [Abstract][Full Text] [Related]
56. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.
Klein NP; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2016 Jun; 35(6):662-72. PubMed ID: 26928521
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
[TBL] [Abstract][Full Text] [Related]
58. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.
Harris SL; Tsao H; Ashton L; Goldblatt D; Fernsten P
Clin Vaccine Immunol; 2007 Apr; 14(4):397-403. PubMed ID: 17287312
[TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
